Good Company,, Some growing pains - Medical Records NeoGenomics Employee Review

4.0
Dec 18, 2025
Recommend
CEO approval
Business Outlook

Pros

Consistent work, leading the charge in cancer diagnosis and research

Cons

Lack of transparency, pay could be better

avatar
NeoGenomics Response
7mo
Thank you for your feedback. We’re proud of the meaningful work our teams do every day and appreciate your recognition of the impact we’re making in advancing cancer diagnosis and research.

Explore other reviews about NeoGenomics

5.0
Mar 11, 2026
Recommend
CEO approval
Business Outlook

Pros

Growing business opportunities for many job seekers

Cons

Ever changing approach on direction on projects

2.0
Mar 2, 2026
Recommend
CEO approval
Business Outlook

Pros

The workforce wants to do the right thing. We take pride in knowing our services impact people's lives everyday.

Cons

Constant turnover, lack of communication throughout - top to bottom. Leadership is struggling and not performing, Most of their attempts to improve growth have lost money. This is factual, not to be mistaken with statements from a disgruntled employee. An article published after the recent earnings release emphasized NEO's 5-year Return on Invested Capital is -10.5%, meaning management doesn't spend our capital wisely. This, along with heavy debt, minimal cash and returns at the bottom of the healthcare sector, should make you pause and do more research before jumping on board.

5
See reviews by: Helpful|Rating|Date|All